On Aug. 20, 2020, CureVac and the European Commission (EC) concluded exploratory talks outlining an Advanced Purchase Agreement (APA) for our potential mRNA-based COVID-19 vaccine. The envisaged contract with the EC was intended to provide all EU Member States with up to 225 million doses and an option for an additional purchase of 180 million doses, to be supplied once our mRNA-based vaccine has proven to be safe and effective against COVID-19.